What does this research mean for the field?

A multidisciplinary approach integrating evidence-based pharmacological and psychosocial interventions, alongside emerging digital and personalized tools, is essential for improving clinical outcomes and addressing diagnostic delays in bipolar disorder. Novelty: ClaimNovelty.SYNTHESIS. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

The aim is to summarize the clinical presentation, diagnosis, and treatment strategies for bipolar disorder.

March 31, 2026Journal of Korean Medical Association1 citationsOpen Access

Trends in pharmacotherapy and guideline comparisons in bipolar disorder: a narrative review

VRVin Ryu

Key Points

The aim is to summarize the clinical presentation, diagnosis, and treatment strategies for bipolar disorder.
Conducted a narrative review on pharmacological and psychosocial strategies.
Discussed clinical characteristics and comorbidities impacting diagnosis.
Reviewed trends in biomarkers and digital health tools for early detection.
Compared guidelines to assess the efficacy and risks of treatments.
Bipolar disorder diagnosed with delays of 5-10 years due to comorbidities and lack of biomarkers.
Core treatments include mood stabilizers, atypical antipsychotics, and selective antidepressants.
Digital health tools and precision psychiatry show promise for improved management.
Multidisciplinary approaches enhance relapse prevention and quality of life.

Abstract

Purpose: This article summarizes the clinical presentation, importance of early diagnosis, pharmacological strategies, psychosocial interventions, and future perspectives of bipolar disorder. It also emphasizes the need for evidence-based multidisciplinary approaches to this chronic mental illness, which has a rising global lifetime prevalence of approximately 0.5%. This review provides a comprehensive overview addressing diagnostic delays (averaging 5–10 years) and comorbidities.Current concepts: Clinically, bipolar disorder is classified into types 1 and 2 and is characterized by recurrent mania/hypomania, depression, and mixed states. Common psychiatric comorbidities (e.g., anxiety disorders) and physical comorbidities (e.g., cardiovascular disease) contribute to diagnostic delays. Challenges in early diagnosis stem from the absence of biomarkers; however, emerging trends include digital health tools (smartphone apps, wearables) and precision psychiatry integrating genetic and neuroimaging data. Core pharmacological treatments include mood stabilizers (lithium, valproate), atypical antipsychotics (quetiapine, aripiprazole), and selective antidepressants. Combination therapy is used for manic episodes, with cautious antidepressant use in depressive episodes to minimize switch risk. Guideline comparisons reveal regional differences and debate on antidepressant efficacy versus risks. Regarding psychosocial interventions, cognitive-behavioral therapy, psychoeducation, and family therapy are effective for relapse prevention, with digital integration representing a forward-looking approach.Discussion and conclusion: Multidisciplinary integration of pharmacological and psychosocial interventions is essential for improving outcomes in bipolar disorder. Promising directions include novel drugs (NRX-101, lumateperone), gene therapy, artificial intelligence-driven personalization, and efforts to address global disparities. However, developing early diagnostic tools and harmonizing guidelines remain key challenges. Evidence-based strategies can minimize relapse and improve quality of life.

问 AI

Bookmark

View Full Paper